Nextage Therapeutics Ltd (NXTG) - Total Liabilities

Latest as of December 2024: ILA5.89 Million ILA ≈ $15.79K USD

Based on the latest financial reports, Nextage Therapeutics Ltd (NXTG) has total liabilities worth ILA5.89 Million ILA (≈ $15.79K USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore NXTG operating cash flow to assess how effectively this company generates cash.

Nextage Therapeutics Ltd - Total Liabilities Trend (2017–2024)

This chart illustrates how Nextage Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Nextage Therapeutics Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Nextage Therapeutics Ltd Competitors by Total Liabilities

The table below lists competitors of Nextage Therapeutics Ltd ranked by their total liabilities.

Company Country Total Liabilities
JPMorgan Claverhouse Investment Trust Plc
LSE:JCH
UK GBX40.51 Million
Witbe Net SA
PA:ALWIT
France €16.43 Million
JLT Mobile Computers AB (publ)
ST:JLT
Sweden Skr29.90 Million
Tissue Repair Ltd
AU:TRP
Australia AU$662.53K
CXApp Inc.
NASDAQ:CXAI
USA $13.31 Million
Till Capital Ltd
V:TIL
Canada CA$147.08K
Global Interactive Technologies, Inc
NASDAQ:GITS
USA $631.22K

Liability Composition Analysis (2017–2024)

This chart breaks down Nextage Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Nextage Therapeutics Ltd worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.05 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.07 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 16.68 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Nextage Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Nextage Therapeutics Ltd (2017–2024)

The table below shows the annual total liabilities of Nextage Therapeutics Ltd from 2017 to 2024.

Year Total Liabilities Change
2024-12-31 ILA5.89 Million
≈ $15.79K
+53.68%
2023-12-31 ILA3.83 Million
≈ $10.27K
+97.73%
2022-12-31 ILA1.94 Million
≈ $5.20K
-48.40%
2021-12-31 ILA3.76 Million
≈ $10.07K
+43.36%
2020-12-31 ILA2.62 Million
≈ $7.02K
+11.49%
2019-12-31 ILA2.35 Million
≈ $6.30K
-67.02%
2018-12-31 ILA7.12 Million
≈ $19.10K
-10.46%
2017-12-31 ILA7.96 Million
≈ $21.33K
--

About Nextage Therapeutics Ltd

TA:NXTG Israel Drug Manufacturers - Specialty & Generic
Market Cap
$5.79 Million
ILA2.16 Billion ILA
Market Cap Rank
#28074 Global
#409 in Israel
Share Price
ILA64.10
Change (1 day)
-17.72%
52-Week Range
ILA64.10 - ILA106.50
All Time High
ILA5080.00
About

Nextage Therapeutics Ltd, a pharmaceutical company, develops cannabinoid-based products. The company was formerly known as Nextage Cannabis Innovation Ltd. and changed its name to Nextage Therapeutics Ltd in August 2020. The company was incorporated in 1982 and is based in Ness Ziona, Israel.